Latest filings (excl ownership)
8-K
Submission of Matters to a Vote of Security Holders
21 May 24
EFFECT
Notice of effectiveness
21 May 24
S-3
Shelf registration
10 May 24
10-Q
2024 Q1
Quarterly report
9 May 24
8-K
Rallybio Reports First Quarter 2024 Financial Results and Provides Business Updates
9 May 24
D
$6.60 mm in equity, sold $6.60 mm, 1 investor
22 Apr 24
DEF 14A
Definitive proxy
11 Apr 24
8-K
Entry into a Material Definitive Agreement
10 Apr 24
S-8
Registration of securities for employees
13 Mar 24
10-K
2023 FY
Annual report
12 Mar 24
8-K
Rallybio Reports Fourth Quarter and Full Year 2023 Financial Results
12 Mar 24
8-K
Rallybio Announces Portfolio Prioritization and Provides Corporate Update
6 Feb 24
8-K
Regulation FD Disclosure
20 Dec 23
10-Q
2023 Q3
Quarterly report
9 Nov 23
8-K
Rallybio Reports Third Quarter 2023 Financial Results and Provides Business Updates
9 Nov 23
10-Q
2023 Q2
Quarterly report
8 Aug 23
8-K
Rallybio Reports Second Quarter 2023 Financial Results and Provides Business Updates
8 Aug 23
8-K
Departure of Directors or Certain Officers
29 Jun 23
8-K
Submission of Matters to a Vote of Security Holders
22 May 23
EFFECT
Notice of effectiveness
15 May 23
424B3
Prospectus supplement
12 May 23
CORRESP
Correspondence with SEC
11 May 23
UPLOAD
Letter from SEC
11 May 23
S-8
Registration of securities for employees
10 May 23
S-3
Shelf registration
9 May 23
10-Q
2023 Q1
Quarterly report
9 May 23
8-K
Rallybio Reports First Quarter 2023 Financial Results
9 May 23
DEF 14A
Definitive proxy
10 Apr 23
10-K
2022 FY
Annual report
6 Mar 23
8-K
Rallybio Reports Fourth Quarter and Full Year 2022 Financial Results
6 Mar 23
8-K
Rallybio Announces Appointment of Jonathan I. Lieber as Chief Financial Officer
31 Jan 23
8-K
Other Events
1 Dec 22
8-K
Entry into a Material Definitive Agreement
14 Nov 22
424B5
Prospectus supplement for primary offering
14 Nov 22
424B5
Prospectus supplement for primary offering
10 Nov 22
10-Q
2022 Q3
Quarterly report
7 Nov 22
8-K
Rallybio Reports Third Quarter 2022 Financial Results
7 Nov 22
8-K
Regulation FD Disclosure
28 Sep 22
EFFECT
Notice of effectiveness
16 Aug 22
424B5
Prospectus supplement for primary offering
15 Aug 22
Latest ownership filings
4
RONALD HUNT
17 May 24
4
Helen M Boudreau
17 May 24
4
Hui Liu
17 May 24
4
KUSH PARMAR
17 May 24
4
Paula Soteropoulos
17 May 24
4
Christine A Nash
17 May 24
4
Robert Lorne Hopfner
17 May 24
4
Wendy Chung
17 May 24
4
Stephen Uden
16 Feb 24
4
MARTIN MACKAY
16 Feb 24
4
Jonathan I Lieber
16 Feb 24
4
Steven Ryder
16 Feb 24
SC 13G/A
VIKING GLOBAL INVESTORS LP
14 Feb 24
SC 13D/A
Pivotal bioVenture Partners Fund I, L.P.
12 Feb 24
SC 13G/A
FMR LLC
9 Feb 24
4
KUSH PARMAR
4 Jan 24
4
RONALD HUNT
4 Jan 24
SC 13G/A
Novo Holdings A/S
2 Jan 24
4
KUSH PARMAR
19 May 23
4
Christine A Nash
19 May 23
4
Helen M Boudreau
19 May 23
4
Robert Lorne Hopfner
19 May 23
4
Paula Soteropoulos
19 May 23
4
Hui Liu
19 May 23
4
RONALD HUNT
19 May 23
4
Wendy Chung
19 May 23
4
Jonathan I Lieber
16 Mar 23
4
KUSH PARMAR
9 Mar 23
4
SCOTT M ROCKLAGE
9 Mar 23
SC 13G/A
FMR LLC
9 Feb 23
4
Stephen Uden
6 Feb 23
4
Steven Ryder
6 Feb 23
4
MARTIN MACKAY
6 Feb 23
SC 13G/A
New Leaf Ventures III, L.P.
6 Feb 23
4
Jonathan I Lieber
1 Feb 23
3
Jonathan I Lieber
1 Feb 23
SC 13G/A
Canaan XI L.P.
1 Feb 23
SC 13G/A
Tekla Capital Management LLC
23 Jan 23
4
Hui Liu
5 Jan 23
4
KUSH PARMAR
5 Jan 23